A Dose Escalation Study to Assess the Safety and Ability of SG1002 to Overcome Circulating Deficits in Hydrogen Sulfide Found in Heart Failure Patients

Trial Profile

A Dose Escalation Study to Assess the Safety and Ability of SG1002 to Overcome Circulating Deficits in Hydrogen Sulfide Found in Heart Failure Patients

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Nov 2014

At a glance

  • Drugs Sodium polysulthionate (Primary)
  • Indications Heart failure
  • Focus Adverse reactions
  • Sponsors Sulfagenix
  • Most Recent Events

    • 04 Nov 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top